Urinary Incontinence: Market Update - Growing Market Brings Opportunities for New Drugs
Pfizer’s aggressive marketing activity to support the launch of Detrol (tolterodine) also successfully raised wider disease awareness. With the two market leading drugs both suffering from poor side-effect profiles, and considerable scope for improved efficacy, there is still considerable unmet need in the market. The report provides an overview of epidemiology of urinary incontinence, by sub-indications, with an evaluation of the potential for expanding the diagnosed population as well as a review of the performance of the leading drugs in the market, Pfizer’s Detrol (tolterodine) and ALZA’s Ditropan XL (oxybutynin chloride). Use this report to gauge the potential of the key late-stage pipeline products, understand the factors driving the urinary incontinence market and evaluate the patient potential in each of the key urinary incontinence sub-indications.
Table of Contents
- TABLE OF CONTENTS - page 3
- EXECUTIVE SUMMARY - page 5
- Introduction - page 5
- Scope and coverage of the Brief - page 5
- Key findings about the the topic - page 6
- Despite strong competition, Pfizer's Detrol will keep its position as market leader with sales of $1,314m in 2011 still well ahead of the chasing pack. However, ALZA's Ditropan XL, currently second in the market, will fall behind Yamanouchi's Vesicare and Novartis's Enablex with sales of $600m - page 6
- The stress urinary incontinence sub-indication will witness the launch of the first drug specifically designed for its treatment in Eli Lilly's duloxetine. As Lilly invests in disease-awareness campaigns to aid its launch the diagnosed population will swell and duloxetine's sales will grow to $488m by 2011 - page 7
- EPIDEMIOLOGY - page 8
- Definition - page 8
- Urge incontinence - page 9
- Urge incontinence vs. overactive bladder - page 10
- Stress incontinence - page 11
- Mixed incontinence - page 11
- Overflow incontinence - page 11
- Urge incontinence - page 9
- Patient potential - page 12
- Segmentation by type of urinary incontinence - page 13
- Overactive bladder - page 14
- Diagnosis - page 16
- Diagnosis rate - page 16
- But is there a need for drug treatment? - page 16
- Pharmacological management of SUI - page 17
- Alpha-adrenergic drugs - page 17
- Tricyclic antidepressants - page 18
- Pharmacological management of urge incontinence - page 18
- Anticholinergic agents - page 18
- Detrol still number one, despite launch of Ditropan XL - page 19
- Definition - page 8
- OPPORTUNITIES FOR PHARMA - page 20
- Pharmacological therapies with improved clinical profiles - page 20
- Effective drug treatments for stress incontinence - page 21
- THE CURRENT MARKET - page 22
- Detrol (tolterodine) - page 22
- Current market position - page 22
- Future growth - page 23
- Ditropan XL (oxybutynin chloride) - page 24
- Opportunities for pipeline products - page 25
- Detrol (tolterodine) - page 22
- PIPELINE POTENTIAL - page 26
- Pipeline overview - page 26
- Vesicare (solifenacin succinate) - page 27
- Marketing - page 27
- Clinical trials - page 27
- Comparison with Detol - page 28
- Enablex (darifenacin) - page 29
- Clinical trials - page 29
- Duloxetine - page 30
- Marketing - page 30
- Clinical trials - page 30
- Market potential - page 31
- Duloxetine forecasts - page 32
- Diagnosis and drug-treatment rates - page 32
- MARKET FORECASTS - page 33
- APPENDIX - page 35
- Bibliography - page 35
- Disclaimer - page 37
- Bibliography - page 35
- List of Tables
- Table 1: Urinary incontinence population in the seven major markets (million), 2002-10 - page 13
- Table 2: Segmentation by type of urinary incontinence - page 14
- Table 3: Overactive bladder population in the seven major markets (million), 2002 - page 15
- Table 4: Urinary incontinence: mid to late-stage pipeline, 2003 - page 26
- Table 5: Comparison of efficacy of Vesicare and Detrol, mean change from baseline to endpoint (episodes/24-hour period) - page 28
- Table 6: US potential SUI market (million), 2004-11 - page 32
- List of Figures
- Figure 1: The four types of urinary incontinence - page 9
- Figure 2: Global urinary incontinence drug sales forecasts ($m), 2002-11 - page 33
Other users found this report page using the following search terms: incontinence overactive bladder urge incontinence stress incontinence incontinence market urinary drug detrol sales vesicare new drugs urge
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.